Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates
- 23 March 2004
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Chemotherapy and Pharmacology
- Vol. 54 (1), 85-88
- https://doi.org/10.1007/s00280-004-0766-5
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Histone Deacetylase in Carcinogenesis and Its Inhibitors as Anti-cancer AgentsBMB Reports, 2003
- Histone-deacetylase inhibitors: novel drugs for the treatment of cancerNature Reviews Drug Discovery, 2002
- Histone deacetylase inhibitors in cancer treatmentAnti-Cancer Drugs, 2002
- Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiationAdvances in Cancer Research, 2002
- Histone deacetylase inhibitors as new cancer drugsCurrent Opinion in Oncology, 2001
- Histone deacetylase inhibitor FK228 inhibits tumor angiogenesisInternational Journal of Cancer, 2001
- P21-dependent G1arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228British Journal of Cancer, 2000
- Histone Acetylation Modifiers in the Pathogenesis of Malignant DiseaseMolecular Medicine, 2000
- FR901228, a Potent Antitumor Antibiotic, Is a Novel Histone Deacetylase InhibitorExperimental Cell Research, 1998
- Action of FR901228, a Novel Antitumor Bicyclic Depsipeptide Produced byChromo-bacterium violaceumNo. 968, on Ha-rasTransformed NIH3T3 CellsBioscience, Biotechnology, and Biochemistry, 1994